Hexahydrocannabinol poisoning reported to French poison centres

References

• Castaneto MS, Gorelick DA, Desrosiers NA, et al. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014;144:12–41. doi: 10.1016/j.drugalcdep.2014.08.005.
   PubMed Web of Science ®Google Scholar
• International Narcotics Control Board. List of psychotropic substances under International Control. Annex to the annual statistical report on psychotropic substances. [internet]. 2022. Available from: https://www.incb.org/documents/Psychotropics/forms/greenlist/2022/Green_List_E.pdf.
   Google Scholar
• Peng J, Fan M, An C, et al. A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD). Basic Clin Pharmacol Toxicol. 2022;130(4):439–456. doi: 10.1111/bcpt.13710.
   PubMed Web of Science ®Google Scholar
• Arrêté du 30 décembre 2021 portant application de l’article R. 5132-86 du code de la santé publique [Internet]. Sect. Texte n°110, JORF n°0304 du 31 décembre 2021. Available from: https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000044793213.
   Google Scholar
• Ujvary I, Ewans-Brown M, Gallegos A, et al. TECHNICAL REPORT hexahydrocannabinol (HHC) and related substances. European Monitoring Centre for Drugs end Drug Addiction; 2023. doi: 10.2810/852912.
   Google Scholar
• Casati S, Rota P, Bergamaschi RF, et al. Hexahydrocannabinol on the light cannabis market: the latest "new" entry. Cannabis Cannabinoid Res. 2022. doi: 10.1089/can.2022.0253.
   PubMedGoogle Scholar
• Nasrallah DJ, Garg NK. Studies pertaining to the emerging cannabinoid hexahydrocannabinol (HHC). ACS Chem Biol. 2023;18(9):2023–2029. doi: 10.1021/acschembio.3c00254.
   PubMed Web of Science ®Google Scholar
• Aviz-Amador A, Contreras-Puentes N, Mercado-Camargo J. Virtual screening using docking and molecular dynamics of cannabinoid analogs against CB1 and CB2 receptors. Comput Biol Chem. 2021;95:107590. doi: 10.1016/j.compbiolchem.2021.107590.
   PubMed Web of Science ®Google Scholar
• Nikas SP, Alapafuja SO, Papanastasiou I, et al. Novel 1′,1′-chain substituted hexahydrocannabinols: 9β-Hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist. J Med Chem. 2010;53(19):6996–7010. doi: 10.1021/jm100641g.
   PubMed Web of Science ®Google Scholar
• Andersson DA, Gentry C, Alenmyr L, et al. TRPA1 mediates spinal antinociception induced by acetaminophen and the cannabinoid Δ9-tetrahydrocannabiorcol. Nat Commun. 2011;2(1):551. doi: 10.1038/ncomms1559.
   PubMedGoogle Scholar
• Järbe TUC, Hiltunen AJ, Lander N, et al. Cannabimimetic activity (Δ1-THC cue) of cannabidiol monomethyl ether and two stereoisomeric hexahydrocannabinols in rats and pigeons. Pharmacol Biochem Behav. 1986;25(2):393–399. doi: 10.1016/0091-3057(86)90015-8.
   PubMed Web of Science ®Google Scholar
• Consroe P, Martin AR, Fish BS. Use of a potential rabbit model for structure-behavioral activity studies of cannabinoids. J Med Chem. 1982;25(5):596–599. doi: 10.1021/jm00347a021.
   PubMed Web of Science ®Google Scholar
• Persson HE, Sjöberg GK, Haines JA, et al. Poisoning severity score. Grading of acute poisoning. J Toxicol Clin Toxicol. 1998;36(3):205–213. doi: 10.3109/15563659809028940.
   PubMed Web of Science ®Google Scholar
• Arrêté du 21 février 2022 relatif au fonctionnement du système d’information des centres antipoison et de toxicovigilance (SICAP) [Internet]. Sect. Texte n° 45, JORF n°0070 Mar 24, 2022. Available from: https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000045398455.
   Google Scholar
• Noble MJ, Hedberg K, Hendrickson RG. Acute cannabis toxicity. Clin Toxicol (Phila). 2019;57(8):735–742. doi: 10.1080/15563650.2018.1548708.
   PubMed Web of Science ®Google Scholar
• Schmid Y, Scholz I, Mueller L, et al. Emergency department presentations related to acute toxicity following recreational use of cannabis products in Switzerland. Drug Alcohol Depend. 2020;206:107726. doi: 10.1016/j.drugalcdep.2019.107726.
   PubMed Web of Science ®Google Scholar
• Consroe P, Martin A, Singh V. Antiepileptic potential of cannabidiol analogs. J Clin Pharmacol. 1981;21(S1):428S–436S. doi: 10.1002/j.1552-4604.1981.tb02623.x.
   PubMedGoogle Scholar
• Russell PB, Todd AR, Wilkinson S, et al. 36. Cannabis indica. Part VII. The relation between chemical constitution and hashish activity. J Chem Soc. 1941:169. doi: 10.1039/jr9410000169.
   Google Scholar
• Adams R, Loewe S, Pease DC, et al. Structure of cannabidiol. VIII. Position of the double bonds in cannabidiol. Marihuana activity of tetrahydrocannabinols. J Am Chem Soc. 1940;62(9):2566–2567. doi: 10.1021/ja01866a510.
   Google Scholar
• Adams R, Loewe S, Smith CM, et al. Tetrahydrocannabinol homologs and analogs with marihuana activity. XIII 1. J Am Chem Soc. 1942;64(3):694–697. doi: 10.1021/ja01255a061.
   Google Scholar
• Edery H, Grunfeld Y, Porath G, et al. Structure-activity relationships in the tetrahydrocannabinol series. Arzneimittelforschung. 1972;22(11):1995–2003.
   PubMed Web of Science ®Google Scholar
• Skinner WA, Rackur G, Uyeno E. Structure-Activity studies on tetrahydro- and hexahydrocannabinol derivatives. J Pharm Sci. 1979;68(3):330–332. doi: 10.1002/jps.2600680319.
   PubMed Web of Science ®Google Scholar